Albin Österroos
Forskningsläkare vid Institutionen för medicinska vetenskaper; Hematologi
- Mobiltelefon:
- 073-203 52 45
- E-post:
- albin.osterroos@medsci.uu.se
- Besöksadress:
- Akademiska sjukhuset, ing 101, plan 4
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ing 100, plan 2
751 85 Uppsala
Forskningsläkare vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Ingrid Glimelius
- Mobiltelefon:
- 073-203 52 45
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
- ORCID:
- 0000-0001-8749-7299
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Min forskning fokuserar på precisionsmedicin för aggressiva hematologiska maligniteter, särskilt akut myeloisk leukemi (AML). Jag strävar efter att integrera kliniska data med avancerad beräkningsbiologi för att genomföra translationella studier som kombinerar epidemiologiska, molekylära och multi-omiska data med hjälp av bioinformatiska tekniker.
Nyckelord
- acute myeloid leukemia
- clinical hematology
- clonal hematopoiesis
- precision medicine
- translational medicine
Publikationer
Senaste publikationer
- Proteome-wide CETSA reveals diverse apoptosisinducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery (2024)
- Delineating functional and molecular impact of ex vivo sample handling in precision medicine (2024)
- Somatic Exonic Deletions in RUNX1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia (2023)
- Prediction model for drug response of acute myeloid leukemia patients (2023)
- Improving prognostication and treatment choices for patients with AML (2023)
Alla publikationer
Artiklar
- Proteome-wide CETSA reveals diverse apoptosisinducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery (2024)
- Delineating functional and molecular impact of ex vivo sample handling in precision medicine (2024)
- Somatic Exonic Deletions in RUNX1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia (2023)
- Prediction model for drug response of acute myeloid leukemia patients (2023)
- A risk score based on real-world data to predict early death in acute promyelocytic leukemia (2022)
- The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia (2021)
- Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia (2020)
- Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years (2020)
- Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia (2016)
- Integrated multi-omic profiling of azacitidine-venetoclax in AML reveals additional targetable pathways to improve the treatment
Böcker
